Data on the management of Grade 3-4 visual disorders due to lorlatinib remain limited. We presented two cases of Grade-4 vision loss due to lorlatinib. We interrupted lorlatinib and initiated a pulse steroid in these patients. In our first patient, visual function improvement was observed three days after treatment, with complete visual function recovery at the end of the first month. However, in the second patient, although vision loss returned to the extent of limited vision from 3 m, no further improvement was noted. In both patients, lorlatinib was continued at a reduced dose because of a favorable response and visual function improvement. In conclusion, the early recognition of vision loss and the interruption of lorlatinib may be effective in the successful recovery of visual function loss. Concurrent steroid therapy may also be beneficial.